Effectiveness and safety of pazopanib (PAZO) and everolimus (EVE) in a changing treatment (Tx) landscape: Interim results of the non-interventional study PAZOREAL.

Boegemann, Martin; Bedke, Jens; Schostak, Martin; Welslau, Manfred; Hering-Schubert, C.; Wolf, Thomas; Schleicher, Jan; Petzold, A; Doehn, Christian; Grüllich, Carsten; GrÃ1⁄4nwald, Viktor; Steiner, Thomas; Ehneß, Rainer; Klein, Dunja; Medinger, Tanja; Goebell, P.J.

doi:10.1200/jco.2018.36.15_suppl.4584

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PAZOREAL shows that this sequence is already being used in clinical practice in Germany, as the majority of patients received nivolumab after pazopanib. This is also in line with clinical trials and previous analyses from PAZOREAL [ 31 , 32 , 33 ]. However, examination of differences between treatment sequences is still needed.…”

Section: Discussionsupporting

confidence: 91%

The Non-Interventional PAZOREAL Study to Assess the Effectiveness and Safety of Pazopanib in a Real-Life Setting: Reflecting a Changing mRCC Treatment Landscape

Doehn

Bögemann

Grünwald

et al. 2022

Cancers

Self Cite

View full text Add to dashboard Cite

The approval of tyrosine kinase inhibitors and checkpoint inhibitors represented a remarkable progression in the therapeutic landscape for the treatment of metastatic renal cell carcinoma (mRCC). Yet, in the ever-evolving landscape of mRCC treatment, real-world data on these agents, including pazopanib, are scarce. The non-interventional PAZOREAL study investigated the effectiveness and safety of pazopanib (first-line), nivolumab (second-line), and everolimus (second- and third-line) in a real-life setting. The multicentric study included 376 mRCC patients who received first-line treatment with pazopanib and assessed time on the drug (primary endpoint), overall survival, best responses, disease control rates, as well as safety signals and health-related quality of life. The median overall time on the drug was 10.0 months, with first-line pazopanib having a median time on drug of 6.3 months. The median overall survival was 35.9 months. The disease control rate for first-line pazopanib was 56.9%. No new safety signals were detected. PAZOREAL provides valuable real-world data for first-line treatment with pazopanib.

show abstract

Section: Discussionsupporting

confidence: 91%